AI assistant
Sending…
Jazz Pharmaceuticals plc — Director's Dealing 2025
Mar 12, 2025
30751_dirs_2025-03-12_1b0c49c2-5229-470d-bc1e-b56a953a9eb6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-03-10
Reporting Person: Iannone Robert (EVP, Global Head of R&D & CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-10 | Ordinary Shares | S | 2403 | $138.4122 | Disposed | 79621 | Direct |
More from Jazz Pharmaceuticals plc
Regulatory Filings
2026
May 29
Annual Report
2026
Apr 24
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2
Director's Dealing
2026
Mar 2